Remission of TP53-Mutant AML After Transplantation With Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Followed by a Donor-Derived Anti-CD33 Chimeric Antigen Receptor T (VCAR33). - Koehne G; Mushtaq MU; Muffly LS; Menes M; Azzi J; Bernard L; Cooper B; Kennedy V; Koura D; Maakaron J; Magenau J; McClune B; et al. (JCO precision oncology, 2025)